• Type:

Cell therapies : do we need more relaxed or more stringent regulations ?

Play
Involved in the acquitision of Bluerock Therapeutics by Bayer in 2019, as Investment Director, Alasdair Thong is a Venture Partner with a strong expertise in iPS-derived cell therapies. We asked him about cell quality and current regulatory standards …

Reviews for Cell therapies : do we need more relaxed or more stringent regulations ?

There are currently no reviews for Cell therapies : do we need more relaxed or more stringent regulations ?
Scroll to top